Preventing bone loss and restoring sexual function in women with early menopause

As many as 1 in every 10 Australian women go through menopause before the age of 45 years. This loss of ovarian function is called early menopause.

Women with early menopause do not produce sufficient estrogen or testosterone necessary for good bone health. They experience progressive bone loss, increasing their risk of osteoporosis (weakened bone strength) and fractures at a young age.

Despite adequate estrogen replacement many women with early menopause also experience sexual dysfunction.
In Australia testosterone therapy is approved for the treatment of postmenopausal women.

There is some evidence that addition of testosterone to estrogen replacement therapy for women with early menopause might prevent bone loss and restore sexual function but more evidence from well conducted trials is needed.

The purpose of this research is to determine whether the use of an approved testosterone therapy, in a dose we have shown restores testosterone levels to those of premenopausal women, prevents bone loss and improves sexual function in women with early menopause who are taking a standard dose of estrogen.

This is a 12-month study using topical testosterone cream applied to the skin on women aged under 45 years with early menopause.

Your participation would involve up to 5 visits with blood collection and bone density scans.

To participate or for further information

Please contact:
Women’s Health Research Program
Monash University
Phone: (03) 9903 0827
Email: womens.health@monash.edu

This study is approved by Monash University Human Research Ethics Committee.